Contact Us

DESTINATION NEWS

Yunovia Announces IND Approval by the MFDS to Initiate Phase 1 MAD Study for the Small Molecule GLP-1 Agonist

Aug 28, 2024

SEOUL,South Korea,Aug. 28,2024-- Yunovia,a drug R&D subsidiary of Ildong Pharmaceutical Group,announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has cleared the IND ap

The 50th JINHAN FAIR: Your Gateway to 2024's Top Home & Gift Trends

Aug 28, 2024

GUANGZHOU,China,Aug. 28,2024-- The 50thJinhan Fair for Home & Gifts (JINHAN FAIR) is set to take place from October 21st to 27th,2024,at Pazhou,Guangzhou,China. This trade show is your gateway to

Shilpa Medicare Makes History: First Indian Company Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20%

Aug 28, 2024

RAICHUR,India,Aug. 28,2024-- In a major breakthrough,Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) proudly announces the successful completion of its Phase 1 clinical trial for its flagship

Use the Royal Navy to help end illegal migration like we did to end slavery, says Tory leadership hopeful Tom Tugendhat as he suggests spending up to £50billion a year on fighting global crisis

Aug 27, 2024

He said it was not 'wrong or nasty to be against illegal migration' and tackling human trafficking gangs was the 'moral thing to do'.

Virtuos expands into the UK with acquisition of Third Kind Games

Aug 27, 2024

Third Kind Games is set to bolster Virtuos\' AAA co-development capabilities,having contributed to titles such as Sea of Thieves and Hearthstone

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC

Aug 27, 2024

CHENGDU,China,Aug. 20,2024--On August 20,the new drug application (NDA) for the core product sacituzumab tirumotecan (sac-TMT,formerly SKB264/MK-2870) based on the positive results from the pivotal Op

1 ... 303 304 305 306 307 308 309 ... 353